Evinacumab · Evkeeza

Monoclonal antibody

Also known as REGN1500

Approvedregulatory verdict

Evidence outlook

Approved: Homozygous Familial Hypercholesterolemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
JP
  • Treatment of homozygous familial hypercholesterolemia
Product first approved 2024PMDA
CA
  • EVKEEZA® (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients 6 months of age and older with homozygous familial hypercholesterolemia (HoFH). The effects of Evkeeza on cardiovascular morbidity and mortality have not been determined.
Product first approved 2023Health Canada
EU
  • Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Homozygous Familial Hypercholesterolemia
NCT05611528 · Daniel Gaudet
2023-02-21 – 2025-03-18 · Homozygous Familial Hypercholesterolemia
What this study did
Phase 2 (5)
Homozygous Familial Hypercholesterolemia
NCT02265952 · Regeneron Pharmaceuticals
2015-02-04 – 2018-07-23 · Homozygous Familial Hypercholesterolemia
What this study did
Other / comorbidity
NCT07271186 · Regeneron Pharmaceuticals
2026-01-09 – 2028-10-13 · Diabetic Kidney Disease (DKD)
What this study did
NCT04863014 · Regeneron Pharmaceuticals
2021-07-12 – 2023-02-15 · Hypertriglyceridemia
What this study did
NCT03175367 · Regeneron Pharmaceuticals
2017-11-10 – 2020-12-14 · Hypercholesterolemia
What this study did
NCT03452228 · Regeneron Pharmaceuticals
2018-06-07 – 2020-07-23 · Severe Hypertriglyceridemia (sHTG)
What this study did
Phase 1 (3)
Other / comorbidity
NCT03146416 · Regeneron Pharmaceuticals
2017-05-16 – 2018-06-14 · Healthy Volunteers
What this study did
NCT01749878 · Regeneron Pharmaceuticals
2012-12 – 2016-01 · Hypertriglyceridemia
What this study did
NCT02107872 · Regeneron Pharmaceuticals
2014-04 – 2015-09 · Metabolic Disorders
What this study did

Competitive landscape

This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Homozygous Familial Hypercholesterolemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Evinacumab (Evkeeza): this drugApprovedMonoclonal antibodyANGPTL3Partial signal
NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5)
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3)
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Reliable signal
NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001
Ezetimibe (Zetia)ApprovedSmall moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Inclisiran (Leqvio)ApprovedRNA / oligonucleotidePCSK9Partial signal
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
Lomitapide (Juxtapid)ApprovedSmall moleculeMTPWeak signal
NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658)
NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16)
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
SHR-1918Phase 3Monoclonal antibodyANGPTL3Partial signal
NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026
ZodasiranPhase 3RNA / oligonucleotideANGPTL3 gene mRNA (hepatic)not yet gradedNo reviewed efficacy summary in this indication
ALN-ANG3
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
BW-00112
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
EDP167
Phase 2(overall)
RNA / oligonucleotideANGPTL3
Weak signal(overall)
No reviewed efficacy summary in this indication
Solbinsiran
Phase 2(overall)
RNA / oligonucleotideANGPTL3
Partial signal(overall)
No reviewed efficacy summary in this indication
SYH2070
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
CTX310
Phase 1(overall)
Gene therapy / editingANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
NNC0491-6075
Phase 1(overall)
Monoclonal antibodyANGPTL3
Weak signal(overall)
No reviewed efficacy summary in this indication
AZD1705
Discontinued
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Evkeeza (Evinacumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Phase 2Diabetic Kidney Disease (DKD)Recruiting
Est. primary completion 2028-10-13 · NCT07271186 · CT.gov ↗
What to watch

See the full readout calendar ↗